An estradiol level of 79 pg/mL is acceptable and within therapeutic range for a 69-year-old woman on estrogen supplementation
The Endocrine Society guidelines explicitly state that clinicians usually do not measure estradiol levels to monitor menopausal hormone therapy (MHT), as treatment is titrated to clinical response rather than laboratory values 1. However, when levels are measured, your value of 79 pg/mL falls within a reasonable therapeutic window.
Context for Interpreting This Level
What the Guidelines Say About Monitoring
The 2015 Endocrine Society Clinical Practice Guideline emphasizes that estradiol monitoring is not standard practice except when symptoms fail to improve with escalating doses, particularly after switching from oral to transdermal administration 1. The overarching principle is to use the lowest effective dose based on clinical response, not laboratory targets.
Your Level in Clinical Context
At 79 pg/mL, this level is:
- Above the postmenopausal range (typically <10-30 pg/mL untreated)
- Well above the minimum threshold for bone protection (research shows 60 pg/mL prevents bone loss 2, with other data suggesting 15 pg/mL may be sufficient 3)
- Below supraphysiologic levels that might raise safety concerns (>200 pg/mL is generally considered high 4)
- Within the range that suppresses menopausal symptoms in most women 3
Evidence-Based Thresholds
Research demonstrates different tissues have varying estradiol sensitivity 3:
- Vasomotor symptom relief: Achieved at very low levels (<15 pg/mL)
- Bone mineral density preservation: Requires ≥15-60 pg/mL 2, 3, 5
- Lipid profile improvement: Requires ≥25 pg/mL for LDL reduction 3
- Gonadotropin suppression: Occurs at <15 pg/mL 3
Your level of 79 pg/mL exceeds all these thresholds, suggesting adequate tissue effects across multiple organ systems.
Important Caveats
Age-Specific Considerations
At 69 years old, you are beyond the typical age for initiating MHT. The USPSTF recommends against using estrogen for chronic disease prevention in postmenopausal women 6, and the WHI Memory Study showed increased dementia risk in women ≥65 years on combined estrogen-progestin therapy 7. If MHT was started after age 60 or more than 10 years past menopause, the risk-benefit ratio shifts unfavorably.
What Matters More Than the Number
Clinical response trumps laboratory values. The critical questions are:
- Are your symptoms (hot flashes, vaginal dryness, etc.) adequately controlled?
- Are you experiencing any adverse effects (breast tenderness, bleeding, bloating)?
- Do you have risk factors that warrant dose reduction (history of VTE, stroke, breast cancer)?
If symptoms are controlled without adverse effects, this level is appropriate regardless of the specific number.
Route of Administration Matters
The guidelines note that transdermal estradiol is preferable for women with VTE risk, hypertension, hypertriglyceridemia, obesity, metabolic syndrome, or diabetes 1. If you're using oral estrogen, consider discussing transdermal options with your provider, as they avoid first-pass hepatic metabolism and associated procoagulant effects.
Practical Recommendations
Continue your current dose if:
- Menopausal symptoms are controlled
- No adverse effects are present
- You have no new contraindications
Consider dose adjustment if:
- Persistent symptoms suggest under-treatment (though unlikely at 79 pg/mL)
- Adverse effects suggest over-treatment (breast tenderness, unscheduled bleeding)
- New risk factors emerge (cardiovascular event, VTE, breast cancer diagnosis)
Reassess the need for continued therapy given your age. The guidelines suggest that when women with premature menopause approach natural menopause age, reassessment and tapering seems reasonable 1. At 69, you are well past natural menopause age, and the indication for continuing MHT should be periodically re-evaluated through shared decision-making with your provider.
The level itself is not concerning, but the appropriateness of continuing any dose of estrogen at age 69 depends on your individual risk profile, symptom burden, and quality of life considerations.